Rilapladib clinical trials
Also written SB-659032.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses rilapladib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rilapladib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's DiseaseCompletedPhase 2GlaxoSmithKlineNCT01428453Written as 250mg rilapladib
- Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy VolunteersWithdrawnPhase 1GlaxoSmithKlineNCT02130661Written as Rilapladib 25 mg
- An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 WeeksCompletedPhase 2GlaxoSmithKlineNCT00695305Written as rilapladib
- Effect Of Rilapladib (SB-659032) On Platelet AggregationCompletedPhase 1GlaxoSmithKlineNCT00387257Written as Rilapladib (SB-659032)
- A Study to Assess the Effect of SB 659032 on Platelet FunctionCompletedPhase 1GlaxoSmithKlineNCT01750827Written as SB659032
Codes
What other systems call rilapladib · ClinicalTrials.gg INT000111
- MeSH (NLM) C000592856rilapladibOne source NLM
- UNII (FDA) O14CWE893ZRILAPLADIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088554rilapladibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76401RilapladibOne source FDA
- DrugBank DB05119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592856 | rilapladib | One source NLM |
| UNII (FDA) | O14CWE893Z | RILAPLADIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088554 | rilapladib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76401 | Rilapladib | One source FDA |
| DrugBank | DB05119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.